sub:assertion {
  d:DB00631 v:identifier "DB00631" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00631" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00631> ;
    dv:drugbank-id "APRD00878" , "DB00631" , "DB07554" ;
    dv:x-atc <http://bio2rdf.org/atc:L01BB06> ;
    dv:x-cas <http://bio2rdf.org/cas:123318-82-1> ;
    dv:x-chebi <http://bio2rdf.org/chebi:681569> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:106472> ;
    dv:x-ndc <http://bio2rdf.org/ndc:58468-0100-1> ;
    dv:x-pdb <http://bio2rdf.org/pdb:CFB> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA164754863> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:119182> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46504968> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Clofarabine> ;
    dct:description """Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed in the U.S. and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra.

Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Some investigations of effectiveness in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) have been carried out."""@en ;
    dct:identifier "drugbank:DB00631" ;
    dct:title "Clofarabine"@en ;
    a dv:Drug ;
    rdfs:label "Clofarabine [drugbank:DB00631]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00631> , <http://www.drugs.com/cdi/clofarabine.html> , <http://www.rxlist.com/cgi/generic3/clofarabine.htm> .
}